CIK 0001583648
- Non-accelerated filer
- Smaller reporting company
PALVELLA THERAPEUTICS, INC.
Sign in to watch- Ticker
- PVLA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- NV
- Entity type
- Operating
- EIN
- 300784346
- Phone
- +1 484-253-1461
- Business address
- 353 W. LANCASTER AVENUE, SUITE 200, WAYNE, PA, 19087
- Former names
- PIERIS PHARMACEUTICALS, INC., Marika Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $11,725,861
- in 7 filings, $11.7M under 10b5-1 plans
Net −$11,725,861. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 9 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-08-30 | Kaufmann Hitto SVP, Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +300,000 | 300,000 | ||
| 2019-07-31 | Said Maya R. Director | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2019-07-25 | Richman Michael Director | Grant or award · Stock Option (right to buy) | +3,789 | $2.89 | $11K | 3,789 |
| 2019-04-25 | Richman Michael Director | Grant or award · Stock Option (right to buy) | +5,640 | $1.94 | $11K | 5,640 |
| 2019-02-26 | Matis Louis Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +96,500 | 96,500 | ||
| 2019-02-26 | Reine Allan Chief Financial Officer | Grant or award · Stock Options (Right to Buy) | +162,500 | 162,500 | ||
| 2019-02-26 | Yoder Stephen S. Chief Executive Officer | Grant or award · Stock Options (Right to Buy) | +380,000 | 380,000 | ||
| 2019-01-30 | BVF PARTNERS L P/IL 10% owner | Other disposition | −2,573,000 | 978,200 | ||
| 2019-01-30 | BVF PARTNERS L P/IL 10% owner | Other disposition | −2,143,000 | 772,324 | ||
| 2019-01-30 | BVF PARTNERS L P/IL 10% owner | Other disposition | −284,000 | 141,346 | ||
| 2019-01-30 | BVF PARTNERS L P/IL 10% owner | Other acquisition · Series B Convertible Preferred Stock, $0.001 par value | +2,573 | 2,573 | ||
| 2019-01-30 | BVF PARTNERS L P/IL 10% owner | Other acquisition · Series B Convertible Preferred Stock, $0.001 par value | +2,143 | 2,143 | ||
| 2019-01-30 | BVF PARTNERS L P/IL 10% owner | Other acquisition · Series B Convertible Preferred Stock, $0.001 par value | +284 | 284 | ||
| 2019-01-25 | Sherman Matthew L Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2019-01-25 | Richman Michael Director | Grant or award · Stock Option (right to buy) | +6,096 | $1.79 | $11K | 6,096 |
| 2019-01-25 | Richman Michael Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2019-01-25 | Prelack Steven Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2019-01-25 | KIRITSY CHRISTOPHER P Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2019-01-25 | Kiener Peter A Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2019-01-25 | BIZZARI JEAN-PIERRE Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 |
Page 14 of 21 · 412 trades